Grifols, S.A (GRF) | Stock Overview & Key Data
Grifols, S.A. | Large-cap | Healthcare
Grifols, S.A. | Large-cap | Healthcare
Grifols, S.A Performance Comparison
Stock Range
Today's Range
Low: €12.85
High: €13.27
on August 4, 2025
52 Week Range
Low: €7.32
High: €13.70
on April 7, 2025
on July 31, 2025
All-Time High: €34.31 on February 17, 2020
Explore how other Spanish stocks compare to their 52-week ranges: View ES Market 52-Week Insights
Key Statistics
Market Cap
€7.9B
EPS
0.44
P/E Ratio (TTM)
29.38
Forward P/E
21.91
P/B Ratio
1.70
PEG Ratio
21.91
Div. Yield
N/A
ROE
4.99%
Beta
1.012
Debt to Equity
117.74
Financial Highlights
Profitability
Gross Margin
39.33%
Operating Margin
18.48%
Profit Margin
4.00%
Returns and Earnings
Return on Assets (TTM)
4.43%
Return on Equity (TTM)
4.99%
EBITDA
€1.4B
Net Income (TTM)
€297.4M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€10.94
Quarterly Revenue Growth (YoY)
4.00%
Quarterly Earnings Growth (YoY)
688.80%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Grifols, S.A GRF | 7.85B Large-cap | 5.04% | 24.21% | 51.58% | 58.65% | 36.68% | 45.94% | -8.10% | -47.67% |
| Laboratorios ROVI | 2.72B Large-cap | -4.32% | -3.89% | 2.11% | -18.23% | -16.95% | -32.81% | 5.98% | 93.27% |
| Almirall S.A ALM | 2.20B Large-cap | -4.66% | -3.76% | 3.02% | 9.75% | 22.20% | 12.65% | 4.49% | 6.67% |
| Pharma Mar S.A PHM | 1.38B Large-cap | -4.11% | -0.06% | 4.90% | -12.96% | -1.00% | 106.70% | 28.61% | -8.80% |
| Faes Farma S.A FAE | 1.34B Large-cap | -2.27% | -4.86% | 0.00% | 22.10% | 22.79% | 21.41% | 9.11% | 23.14% |
| Clinica Baviera S.A CBAV | 710.76M Mid-cap | 1.37% | 6.47% | 21.98% | 32.93% | 40.95% | 55.24% | 122.00% | 360.10% |
Ownership & Short Interest
Insider Ownership
31.05%
Institutional Ownership
29.95%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
2M
Average 90-Day Volume
2M
Grifols, S.A Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Grifols, S.A would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is GRF's 52-week high and low?
- In the last 52 weeks, Grifols, S.A reached a high of €13.70 (on July 31, 2025) and a low of €7.32 (on April 7, 2025).
- What is the market cap and P/E ratio for GRF?
- Curious about Grifols, S.A's size and valuation? Its market capitalization stands at 7.85B. When it comes to valuation, the P/E ratio (trailing twelve months) is 29.38, and the forward P/E (looking ahead) is 21.91.
- Does GRF pay dividends? If so, what's the yield?
- As for dividends, Grifols, S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Grifols, S.A's main competitors or similar companies to consider before investing?
When looking at Grifols, S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Laboratorios
ROVI2.72B Healthcare Drug Manufacturers - Specialty & Generic -32.81% 5.98% Almirall S.A
ALM2.20B Healthcare Drug Manufacturers - Specialty & Generic 12.65% 4.49% Pharma Mar S.A
PHM1.38B Healthcare Biotechnology 106.70% 28.61% Faes Farma S.A
FAE1.34B Healthcare Drug Manufacturers - Specialty & Generic 21.41% 9.11% Clinica Baviera S.A
CBAV710.76M Healthcare Diagnostics & Research 55.24% 122.00% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Grifols, S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Grifols, S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 4.99%, the Debt to Equity ratio from the most recent quarter is 117.74, and its Gross Profit Margin stands at 39.33%.
- What is the recent revenue and earnings growth for GRF?
- Looking at Grifols, S.A's growth, its revenue over the trailing twelve months (TTM) was €7B. Compared to the same quarter last year (YoY), quarterly revenue grew by 4.00%, and quarterly earnings saw a YoY growth of 688.80%.
- How much of GRF stock is held by insiders and institutions?
- Wondering who owns Grifols, S.A stock? Company insiders (like executives and directors) hold about 31.05% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 29.95%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.